A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia
Authors
Yunfei Chen•Yuhua Wang•Lei Zhang
Journal
New England Journal of Medicine
Published
June 19, 2024
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by autoantibody-mediated platelet destruction. Treatment with CM313, a novel anti-CD38 monoclonal antibody, can result in targeted clearance of CD38-positive cells, including plasma cells.